Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan and Capecitabine in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) is a phase 3 interventional study registered as NCT06393374 by Merck Sharp & Dohme LLC, with 1530 participants planned, started 2024-06-24 and due to reach its primary completion in 2030-12-16. Interventions recorded: Pembrolizumab, Sacituzumab tirumotecan and Capecitabine.
Similar pages
not linked directly; found by shared links- TrialA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Shares Sacituzumab tirumotecan, Capecitabine, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Triple-negative breast cancer (TNBC), Pembrolizumab and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Shares Capecitabine, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Shares Capecitabine, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Triple-negative breast cancer (TNBC), Pembrolizumab and the tag pipeline.
- TrialSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Shares Sacituzumab tirumotecan, Capecitabine, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD) and the tag pipeline.